Santaris enters the cardiovascular arena with microRNA licence
This article was originally published in Scrip
Executive Summary
Santaris Pharma of Denmark is steaming ahead with its development of RNA-targeted medicines by obtaining an exclusive licence for the intellectual property related to the regulation of the miR-33 microRNA for the treatment of cardiovascular disorders from Massachusetts General Hospital (MGH).